Brief: Simcere Zaiming Announces Clinical Collaboration To Evaluate SIM0235 In Phase 1 Trial

Simcere Pharmaceutical

14/03/2023 13:31

March 14 (Reuters) - Simcere Pharmaceutical Group Ltd
 2096.HK :
    * SIMCERE ZAIMING ANNOUNCES CLINICAL COLLABORATION TO
EVALUATE
SIM0235, A TNFR2 MONOCLONAL ANTIBODY, IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB) IN A PHASE 1 TRIAL IN ADVANCED SOLID
TUMORS AND CUTANEOUS T-CELL LYMPHOMA
    * SIMCERE PHARMACEUTICAL - SIMCERE ZAIMING, CO OF SIMCERE
ENTERED
INTO CLINICAL COLLABORATION AGREEMENT WITH MERCK & CO., INC.,
RAHWAY, NJ, USA (MSD)
    * SIMCERE PHARMACEUTICAL - UNDER TERMS OF AGREEMENT, MSD
WILL
SUPPLY KEYTRUDA AND COLLABORATE WITH SIMCERE ZAIMING ON THIS
STUDY
    * SIMCERE PHARMACEUTICAL - SIMCERE ZAIMING RETAINS ALL
WORLDWIDE
COMMERCIAL RIGHTS TO SIM0235

Source text for Eikon:  ID:nPnbbcwwMa 
Further company coverage:  2096.HK 

 ((Reuters.Briefs@thomsonreuters.com;))